Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Axia Vegetable Seeds develops and sells high-quality vegetable seed varieties—primarily tomatoes—for protected greenhouse cultivation. The company uses advanced breeding techniques to create new hybrids with improved taste, yield, and disease resistance. It has a global presence with R&D facilities in the Netherlands and breeding/testing stations in Spain and Italy. Recent focus includes developing tomato varieties resistant to ToBRFV virus. In 2025 the open-field business under the US Agriseeds brand was acquired by Namdhari Seeds; however, Axia continues its core protected culture seed business independently. The company does not operate in human therapeutics, therefore, there are no clinical results or a drug pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Axia Vegetable Seeds.